Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control

Executive Summary

California-based Tizona has begun 2019 by installing a new CEO and winning a lucrative early-stage R&D pact with AbbVie aimed at commercializing cancer therapies targeting the immune system-suppressing enzyme CD39.

You may also be interested in...



Gilead Gets Option To Tizona's Novel HLA-G Checkpoint, Further Bulking Up Immune Checkpoint Arsenal

The big biotech will pay $300m to acquire a 49.9% equity interest in the cancer immunotherapy startup with a buyout option. It is one of several immune checkpoints Gilead has secured access to this year.

Finance Watch: Multiple VC Mega-Rounds Fund T-Cell, Hearing, IO, Fibrosis Therapies

Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.

AbbVie’s Downward Humira Guidance Worries Analysts

Decreasing Humira’s ex-US sales guidance for the second time in three months caught significant attention, as AbbVie now expects 30% revenue erosion for its top-seller outside its home market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel